Trial Profile
PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 10 Mar 2011 New trial record